More info
Active ingredients
Umifenovir
Release form
Capsules
Composition
Active ingredient: Umifenovir Concentration of active ingredient (mg): 100 mg
Pharmacological effect
Antiviral drug. It specifically inhibits influenza A and B viruses, a coronavirus associated with severe acute respiratory syndrome (SARS-associated coronavirus). The mechanism of antiviral action refers to fusion inhibitors (fusions), interacts with the hemagglutinin of the virus and prevents the fusion of the lipid envelope of the virus and cell membranes. It has a moderate immunomodulatory effect. It has interferon-inducing activity, stimulates humoral and cellular immunity reactions, the phagocytic function of macrophages, increases the body's resistance to viral infections. Reduces the incidence of complications associated with viral infection, as well as exacerbations of chronic bacterial diseases. Therapeutic efficacy in viral infections manifests itself in reducing the severity of general intoxication and clinical phenomena, reducing the duration of the disease. It has a moderate immunomodulating effect. Applies to low-toxic drugs (LD50> 4 g / kg). It does not have any negative effects on the human body when administered orally at recommended doses.
Pharmacokinetics
Absorption and distributionQuickly absorbed from the gastrointestinal tract. C max in plasma with the use of umifenovir in a dose of 50 mg is achieved in 1.2 hours, in a dose of 100 mg - 1.5 hours. Umifenovir is rapidly distributed throughout the organs and tissues of the body. Metabolism and elimination Metabolized in the liver. T1 / 2 is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in small amounts by the kidneys (0.12%). During the first day, 90% of the received dose is displayed.
Indications
Prevention and treatment in adults and children: - influenza A and B, SARS, SARS, including those complicated by bronchitis and pneumonia; - secondary immunodeficiency states; - complex therapy of chronic bronchitis, pneumonia and recurrent herpetic infection. Prevention of postoperative infectious complications and normalization of the immune status. As part of the complex treatment of acute intestinal infections of rotavirus etiology in children over 3 years old.
Contraindications
- children's age up to 3 years; - hypersensitivity to the drug.
Precautionary measures
Do not exceed recommended doses.
Use during pregnancy and lactation
Data on the use of Arbidol during pregnancy and during breastfeeding is not provided.
Dosage and administration
The drug is prescribed inside, before meals. A single dose for adults and children over 12 years old - 200 mg (2 capsules 100 mg each or 4 capsules 50 mg each), for children aged 6 to 12 years old - 100 mg, from 3 to 6 years old - 50 mg. For non-specific prophylaxis In direct contact with a sick flu and other acute respiratory viral infections to adults and children over 12, Arbidol is prescribed at a dose of 200 mg / day; children aged 6 to 12 years - 100 mg / day; children aged 3 to 6 years - 50 mg / day. The drug is taken 1 time / day. The course is 10-14 days. During the epidemic of influenza and other acute respiratory viral infections, for the prevention of exacerbation of chronic bronchitis and recurrence of herpes infection in adults and children over 12 years old, the drug is prescribed in a single dose of 200 mg; children aged 6 to 12 years - 100 mg; children aged 3 to 6 years - 50 mg. The drug is taken 2 times a week for 3 weeks. For the prevention of SARS (in contact with patients), adults and children over 12 years old are prescribed 200 mg 1 time per day for 12-14 days; children aged 6 to 12 years old - 100 mg 1 time / day (before meals) for 12-14 days. For the prevention of postoperative infectious complications, the drug is prescribed for two days before surgery, then on the second and fifth day after surgery in doses: adults and children over 12 years old - 200 mg, children aged 6 to 12 years - 100 mg, 3 to 6 years - 50 mg. For treatment For flu and other acute respiratory viral infections without complications, adults and children over 12 years old should be prescribed 200 mg 4 times / day (every 6 hours), children aged 6 to 12 years old - 100 mg 4 times / day (every 6 hours) , from 3 to 6 years - 50 mg 4 times / day (every 6 hours). The course of treatment is 5 days. For influenza and other acute respiratory viral infections with complications (including bronchitis, pneumonia), adults and children over 12 years old should take Arbidol 200 mg 4 times / day (every 6 hours) for 5 days, then 200 mg 1 time. / week within 4 weeks. Children from 6 to 12 years old are prescribed 100 mg 4 times / day (every 6 hours) and then 100 mg 1 time / week. within 4 weeks. Children from 3 to 6 years old should be prescribed 50 mg 4 times / day (every 6 hours) for 5 days, then 50 mg 1 time / week. within 4 weeks. For the treatment of SARS, adults and children over 12 years old are prescribed 200 mg 2 times / day for 8-10 days. In the complex therapy of chronic bronchitis and recurrent herpetic infection in adults and children over 12 years old, the drug is prescribed 200 mg 4 times / day (every 6 hours) for 5-7 days, then 200 mg 2 times / week. within 4 weeks.Children aged 6 to 12 years, 100 mg 4 times / day (every 6 hours) for 5-7 days, then 100 mg 2 times / week. within 4 weeks. Children aged 3 to 6 years old are prescribed 50 mg 4 times / day (every 6 hours) for 5-7 days; then - 50 mg 2 times / week. within 4 weeks. As part of the complex treatment of acute intestinal infections of rotavirus etiology, children over 12 years old are prescribed 200 mg 4 times / day (every 6 hours) for 5 days, between 6 and 12 years old - 100 mg 4 times / day (every 6 hours) ) for 5 days, at the age of 3 to 6 years - 50 mg 4 times / day (every 6 hours) for 5 days.
Side effects
Seldom: allergic reactions.
Overdose
Cases of drug overdose are not marked.
Interaction with other drugs
When prescribing with other drugs, no negative effects were noted.
special instructions
Influence on the ability to drive motor vehicles and control mechanisms. The drug does not show central neurotropic activity and can be used in medical practice for preventive purposes in practically healthy people of various professions requiring increased attention and psychomotor speed (including transport drivers, operators).